Calquence Japan approval for treatment-naïve CLL
28 December 2022 07:05 GMT Calquence approved in Japan for adults withtreatment-naïve chronic lymphocytic leukaemia Calquence significantly increased the time patients lived without disease progression or death vs. chemoimmunotherapy AstraZeneca's Calquence (acalabrutinib), a selective Bruton's tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with treatment-naïve chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL]). Calquence was previously approved